Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders

NCT00437086 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00437086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00437086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
November 30, 2008
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia